Effect of Atorvastatin and Spironolactorne on peritoneal fibrosis

Objective To investigate the prevention and treatment of peritoneal fibrosis in long-term peritoneal dialysis patients. Methods We randomly and equally divided 50 Wistar male rats into 5 groups. Rats in group A were intraperitoneally infected with 0.9% normal saline daily as control group. Rats in groups B, C, D and E were intraperitoneally injected with 4.25% Batter dialysate 20ml daily, and infected with Erythromycin lactobionate 62,500 units on the 7th, 14th, 21st and 28th days of the treatment; Additionally, rats in group C were given Spironolactone 100mg/kg daily by gastric gavage, those in group D Atrovastatin 20 mg/kg daily by gastric gavage, and those in group E Spironolactone 100mg/kg daily as well as Atrovastatin 20 mg/kg daily by gastric gavage. TGF β 1 in the peritoneal fluid was measured on the 1st and 30th days of the treatment. Rats were sacrificed on the 30th day of the treatment. Pathological change of peritoneal membrane, 2-hour peritoneal equilibration test (PET), eNOS expression and angiogenesis by immunohistochemistry in peritoneal membrane were examined in these rats. Results Thickness of peritoneal membrane was less in groups C, D and E than in group B (P0.05), so did the eNOS expression (P 0.05) and the angiogenesis in peritoneal membrane. TGF-β1 was significantly higher in group B, than in groups C, D and E (P 0.05). Conclusion Both Spironolactone and Atorvastatin are useful for the prevention and treatment of peritoneal fibrosis.